BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28847988)

  • 1. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
    Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
    Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma.
    Mohanty S; Kumar A; Das P; Sahu SK; Choudhuri T
    Apoptosis; 2017 Sep; 22(9):1098-1115. PubMed ID: 28653223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
    Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
    J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
    Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
    Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
    Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
    Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.
    Chen HS; De Leo A; Wang Z; Kerekovic A; Hills R; Lieberman PM
    PLoS Pathog; 2017 Jan; 13(1):e1006100. PubMed ID: 28107481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.
    Chandrasekharan JA; Huang XM; Hwang AC; Sharma-Walia N
    J Virol; 2016 Dec; 90(24):11020-11031. PubMed ID: 27681120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research].
    Watanabe T; Fujimuro M
    Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
    Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M
    Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
    Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
    mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CADM1 is essential for KSHV-encoded vGPCR-and vFLIP-mediated chronic NF-κB activation.
    Hunte R; Alonso P; Thomas R; Bazile CA; Ramos JC; van der Weyden L; Dominguez-Bendala J; Khan WN; Shembade N
    PLoS Pathog; 2018 Apr; 14(4):e1006968. PubMed ID: 29698475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional
    Park A; Oh S; Jung KL; Choi UY; Lee HR; Rosenfeld MG; Jung JU
    Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21618-21627. PubMed ID: 32817485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
    Zhang YJ; Patel D; Nan Y; Fan S
    Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Subcellular Localization of the Kaposi's Sarcoma-Associated Herpesvirus K15P Protein during Latency and Lytic Reactivation in Primary Effusion Lymphoma Cells.
    Smith CG; Kharkwal H; Wilson DW
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
    Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC
    J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
    Sarosiek KA; Cavallin LE; Bhatt S; Toomey NL; Natkunam Y; Blasini W; Gentles AJ; Ramos JC; Mesri EA; Lossos IS
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13069-74. PubMed ID: 20615981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress induces reactivation of Kaposi's sarcoma-associated herpesvirus and death of primary effusion lymphoma cells.
    Li X; Feng J; Sun R
    J Virol; 2011 Jan; 85(2):715-24. PubMed ID: 21068240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.